TAGLN Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q01995 |
---|---|
Clone Names | 80924228 |
Gene ID | 6876 |
---|---|
Other Names | Transgelin, 22 kDa actin-binding protein, Protein WS3-10, Smooth muscle protein 22-alpha, SM22-alpha, TAGLN, SM22, WS3-10 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP6678a was selected from the N-term region of human TAGLN. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | TAGLN |
---|---|
Synonyms | SM22, WS3-10 |
Function | Actin cross-linking/gelling protein (By similarity). Involved in calcium interactions and contractile properties of the cell that may contribute to replicative senescence. |
Cellular Location | Cytoplasm. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
TAGLN is a transformation and shape-change sensitive actin cross-linking/gelling protein found in fibroblasts and smooth muscle. Its expression is down-regulated in many cell lines, and this down-regulation may be an early and sensitive marker for the onset of transformation. A functional role of this protein is unclear.
References
Zhao,L., Mod. Pathol. 22 (6), 786-796 (2009)Leguillette,R., Am. J. Respir. Crit. Care Med. 179 (3), 194-204 (2009)Yu,H., FASEB J. 22 (6), 1778-1789 (2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.